Century Therapeutics (IPSC) Equity Average (2022 - 2025)
Historic Equity Average for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $193.1 million.
- Century Therapeutics' Equity Average fell 755.02% to $193.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.1 million, marking a year-over-year decrease of 755.02%. This contributed to the annual value of $173.1 million for FY2024, which is 2900.09% down from last year.
- Per Century Therapeutics' latest filing, its Equity Average stood at $193.1 million for Q3 2025, which was down 755.02% from $225.2 million recorded in Q2 2025.
- Century Therapeutics' Equity Average's 5-year high stood at $372.3 million during Q2 2022, with a 5-year trough of $178.5 million in Q4 2024.
- For the 4-year period, Century Therapeutics' Equity Average averaged around $243.5 million, with its median value being $217.0 million (2024).
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 3746.77% in 2024, then soared by 1258.79% in 2025.
- Century Therapeutics' Equity Average (Quarter) stood at $316.5 million in 2022, then crashed by 36.17% to $202.0 million in 2023, then dropped by 11.62% to $178.5 million in 2024, then grew by 8.18% to $193.1 million in 2025.
- Its Equity Average stands at $193.1 million for Q3 2025, versus $225.2 million for Q2 2025 and $200.9 million for Q1 2025.